PUBLICATIONS
“The joy of discovery is certainly the liveliest that the mind of man can ever feel”
- Claude Bernard -
2023年
Haruka Wada, Ryo Otsuka, Wilfred T V Germeraad, Tomoki Murata, Toru Kondo, Ken-ichiro Seino.
Tumor cell-induced macrophage senescence plays a pivotal role in tumor initiation followed by stable growth in immunocompetent condition.
J Immunother Cancer 2023;11:e006677. doi:10.1136/jitc-2023-006677
がん幹細胞はマクロファージに細胞老化を誘導することで免疫からの攻撃から免れ腫瘍を形成する
Nabeel Kajihara, Yunqi Ge & Ken-ichiro Seino.
Blocking of oestrogen signals improves anti-tumour effect regardless of oestrogen receptor alpha expression in cancer cells.
Br J Cancer 2023. https://www.nature.com/articles/s41416-023-02381-0
腫瘍細胞のエストロゲン受容体（ER）発現に関わらず抗エストロゲン薬がエフェクターT細胞の機能を改善させ、腫瘍微小環境の免疫状態を改善することで抗腫瘍効果を高めることを解明しました
Han N, Wada H, Kobayashi T, Otsuka R, Seino K. A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin.
Oncoimmunology 2023. https://doi.org/10.1080/2162402X.2023.2238499
がん細胞そのものに作用する抗がん剤ならびに放射線治療の効果をIL-34が大きく左右すること並びにそのメカニズムを解明しました
Rishu Takimoto, Hiroki Sugie, Ken-ichiro Seino, et al. for the CITEG.
Safety evaluation of immune-cell therapy for malignant tumor in the Cancer Immune-cell Therapy Evaluation Group (CITEG).
Cytotherapy 2023. https://doi.org/10.1016/j.jcyt.2023.06.007
長年共同研究を行ってきた臨床免疫細胞治療の安全性に関する論文が発表されました
Murata T, Hama N, Kamatani T, Mori A, Otsuka R, Wada H, and Seino K.
iPSC-derived hematopoietic stem and progenitor cells induce mixed chimerism and donor-specific allograft tolerance.
Am J Transplantation 2023. doi: 10.1016/j.ajt.2023.05.020.
長年の研究の末、iPS細胞から免疫寛容を誘導する細胞（iHSPC）を作り出し、ドナー特異的な免疫寛容の誘導に成功しました
Kajihara N, Tanaka Y, Takeuchi R, Kobayashi T, Ataka T, Nakano S, Yamada T, Takaoka A, Hasegawa Y, Seino K, and Wada H. Augmented interferon regulatory factor 7 axis in whole tumor cell vaccines prevents tumor recurrence by inducing interferon gamma-secreting B cells.
Oncoimmunology 2023. doi.org/10.1080/2162402X.2023.2213132
以前に報告した細胞株4T1-Sがワクチン効果を発揮するメカニズムを明らかにしました
Murata T, Otsuka R, Sasaki A, Kamatani T, Wada H, Yamakawa H, Hasegawa Y, and Seino K.
Induction of allograft tolerance by adoptive transfer of donor B cells: an immune regulatory strategy for transplantation using MHC-matched iPS cells.
Int Immunol 2023. doi.org/10.1093/intimm/dxad008
ドナーB細胞を用いたdonor specific transfusionによりiPS細胞を用いた移植で免疫寛容の誘導に成功しました
2022年
Nakamura T, Kajihara N, Hama N, Kobayashi T, Otsuka R, Han N, Wada H, Hasegawa Y, Suzuki N, Seino K.
Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.
J Gynecol Oncol. 2022 Dec 21. doi: 10.3802/jgo.2023.34.e25.
PARP阻害剤の効果をIL-34が制御していることを発見
Kajihara N, Kobayashi T, Otsuka R, Nio-Kobayashi J, Oshino T, Takahashi M, Imanishi S, Hashimoto A, Wada H, Seino K.
Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.
Cancer Immunol Immunother 2022 Sep 14. doi: 10.1007/s00262-022-03293-3.
TNBCにおける治療抵抗性の形成にIL-34が誘導するMDSCが重要
Tomoki Kamatani, Ryo Otsuka, Tomoki Murata, Haruka Wada, Takeshi Takahashi, Akihiro Mori, Soichiro Murata, Hideki Taniguchi and Ken-ichiro Seino.
Evaluation of immunosuppression protocols for MHC-matched allogeneic iPS cell-based transplantation using a mouse skin transplantation model.
Inflamm Regener 2022, 42:4. doi.org/10.1186/s41232-021-00190-7
iPS細胞を用いた移植ではどのような免疫抑制療法が良いのか？に答える重要な論文。
2021年
Hase K, Namba K, Wada H, Tsuji H, Maeda A, Murata T, Otsuka R, Iwata D, Kanda A, Noda K, Kitaichi N, Seino K, Ishida S.
Macrophage-like iPS-derived Suppressor Cells Reduce Th1-mediated Immune Response to a Retinal Antigen.
Curr Eye Res. 2021 Dec;46(12):1908-1916.
北大眼科との共同研究。iPS細胞由来免疫抑制細胞を応用していただきました。
Otsuka R, Wada H, Seino K.
IL-34, the rationale for its expression in physiological and pathological conditions.
Seminars in Immunology 101517, 2021
IL-34に関する新しい総説です。内容に自信あり！
Nanumi Han, Hye Yoon Jang, Naoki Hama, Takuto Kobayashi, Ryo Otsuka, Haruka Wada, Ken-ichiro Seino.
An optimized protocol for patient-derivedxenograft in humanized mice to evaluate therole of IL-34 in immunotherapeutic resistance.
STAR Protocols 2:100460, 2021. https://doi.org/10.1016/j.xpro.2021.100460
免疫ヒト化マウスを用いたPDXモデル作製プロトコールです。
Mori A, Murata S, Tashiro N, Tadokoro T, Okamoto S, Otsuka R, Wada H, Murata T, Takahashi T, Seino K, and Taniguchi H.
Establishment of Human Leukocyte Antigen-Mismatched Immune Responses after Transplantation of Human Liver Bud in Humanized Mouse Models.
Cells 10:476, 2021. https://doi.org/10.3390/cells10020476.
ヒトiPS細胞由来肝芽がアロ免疫系によって拒絶される実験系を世界で初めて樹立。
Koyama I, Bashuda H, Uchida K, Seino K, Habu S, Nakajima I, Fuchinoue S, Okumura K, Teraoka S.
Clinical Trial With Adoptive Transfer of Ex Vivo-induced, Donor-specific Immune-regulatory Cells in Kidney Transplantation-A Second Report.
Transplantation. 2020 Nov;104(11):2415-2423.
2020年
Naoki Hama, Takuto Kobayashi, Nanumi Han, Fumihito Kitagawa, Nabeel Kajihara, Ryo Otsuka, Haruka Wada, Hee-kyung Lee, Hwanseok Rhee, Yoshinori Hasegawa, Hideo Yagita, Muhammad Baghdadi, Ken-ichiro Seino.
Interleukin-34 limits the therapeutic effects of immune checkpoint blockade.
iScience 23:101584, 2020
抗PD-1抗体や抗CTLA-4抗体による免疫治療の効果をIL-34が阻害することを初めて明らかにしました。
Tomoki Murata, Haruka Wada, Ryo Otsuka, Airi Sasaki, Hyuma Tsuji, Mizuho Itoh, Nanami Eguchi, Tatsuo Kawai, Ken-ichiro Seino.
Establishment of an experimental model for MHC homo-to-hetero transplantation.
Scientific Reports 10:13560, 2020
HLAホモiPS細胞ストック事業を想定した初めての動物モデルを確立。同モデルを活用して、重要なことを明らかにしていきます。
Hyuma Tsuji, Ryo Otsuka, Haruka Wada, Tomoki Murata, Airi Sasaki, Mizuho Itoh, Muhammad Baghdadi, Erika Sasaki, Ken-ichiro Seino.
Induction of macrophage-like immunosuppressive cells from common marmoset ES cells by stepwise differentiation with DZNep.
Scientific Reports 10:12625, 2020
霊長類（マーモセット）ES細胞から免疫抑制性細胞の作製に成功しました。
Ryo Otsuka and Ken-ichiro Seino.
Macrophage activation syndrome and COVID-19.
Inflammation and Regeneration 40:19, 2020
我が研究室からもCOVID-19におけるマクロファージ活性化症候群に関するReview論文を発表しました。
Hideyuki Okano and Ken-ichiro Seino.
Steps towards COVID-19 suppression.
Inflammation and Regeneration 40:13, 2020. https://doi.org/10.1186/s41232-020-00120-z
Inflammation & Regeneration誌で編集長の岡野先生とともにCOVID-19特集を編纂しました。重要な論文ばかり揃っています。
Nabeel Kajihara, Fumihito Kitagawa, Takuto Kobayashi, Haruka Wada, Ryo Otsuka, Ken-ichiro Seino.
Interleukin-34 contributes to poor prognosis in triple negative breast cancer.
Breast Cancer (2020). https://doi.org/10.1007/s12282-020-01123-x
トリプルネガティブ乳がんにはIL-34が高発現してる。新しい治療ターゲットになる可能性を示した重要な論文。
Nanumi Han, Delnur Anwar, Naoki Hama, Takuto Kobayashi, Hidefumi Suzuki, Hidehisa Takahashi, Haruka Wada, Ryo Otsuka, Muhammad Baghdadi, Ken-ichiro Seino.
Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells.
Inflamm Regener 40, 25 (2020). https://doi.org/10.1186/s41232-020-00129-4
IL-34の転写制御にBrd4が重要、JQ1で抑制可能。IL-34の薬剤による制御の可能性を示した重要な論文。
小林拓斗、大塚亮、清野研一郎.
IL-34とマクロファージ.
医学のあゆみ 273:993-998, 2020
Ryo Otsuka, Haruka Wada, Tomoki Murata, and Ken-ichiro Seino.
Immune reaction and regulation in transplantation based on pluripotent stem cell technology.
Inflammation and Regeneration 40:12, 2020
当研究室で進めているiPS細胞を用いた移植における免疫制御に関するReview論文。再生医療における重要課題です。
Ryo Otsuka, Haruka Wada, Hyuma Tsuji, Airi Sasaki, Tomoki Murata, Mizuho Itoh, Muhammad Baghdadi, Ken-ichiro Seino.
Efficient generation of thymic epithelium from induced pluripotent stem cells that prolongs allograft survival.
Scientific Reports 10, 2242 (2020) https://doi.org/10.1038/s41598-019-57088-1
iPS細胞からの移植において免疫寛容を誘導しようとする試みの一つ。iPS細胞から胸腺上皮細胞を効率的に作製し、移植拒絶を抑制しました。
2019年
Haruka Wada, Yuhei Shibata, Yurika Abe, Ryo Otsuka, Nanami Eguchi, Yoshimi Kawamura, Kaori Oka, Muhammad Baghdadi, Tatsuya Atsumi, Kyoko Miura, and Ken-ichiro Seino.
Flow cytometric identification and cell-line establishment of macrophages in naked mole-rats.
Scientific Reports 9:17981, 2019
Takuto Kobayashi, Muhammad Baghdadi, Nanumi Han, Tomoki Murata, Naoki Hama, Ryo Otsuka, Haruka Wada, Manabu Shiozawa, Tomoyuki Yokose, Yohei Miyagi, Atsushi Takano, Yataro Daigo, Ken-ichiro Seino.
Prognostic value of IL-34 in colorectal cancer patients.
Immunological Medicine 42:169-175, 2019
大腸癌におけるIL-34の発現は、多変量解析で単独の予後不良因子であることを示している重要な論文
Hiraku Endo, Naoki Hama, Muhammad Baghdad, Kozo Ishikawa, Ryo Otsuka Haruka Wada, Hiroshi Asano, Daisuke Endo, Yosuke Konno, Tatsuya Kato, Hidemichi Watari, Akiko Tozawa, Nao Suzuki, Tomoyuki Yokose, Atsushi Takano, Hisamori Kato, Yohei Miyagi, Yataro Daigo, Ken-ichiro Seino.
Interleukin-34 expression in ovarian cancer: A possible correlation with disease progression.
International Immunology doi:10.1093/intimm/dxz074, 2019
臨床検体ならびにマウスモデルを用い、卵巣がんにおけるIL-34の病的意義を初めて示しました。
Muhammad Baghdadi, Kozo Ishikawa, Sayaka Nakanishi, Yosuke Kameda, Yui Umeyama, Hiraku Endo, Haruka Wada, Bjarne Bogen, Satoshi Yamamoto, Keisuke Yamaguchi, Ikumi Kasahara, Hiroshi Iwasaki, Makoto Ibata, Hideki Goto, Shuichiro Takahashi, Takanori Teshima, Ken-ichiro Seino.
A role for IL-34 in osteolytic disease of multiple myeloma.
Blood Advances 2019 3:541-551; doi: https://doi.org/10.1182/bloodadvances.2018020008
骨髄腫の骨病変におけるIL-34の役割を世界で初めて解明。
プレスリリース：https://www.amed.go.jp/news/release_20190220-01.html
2018年
Komohara Y, Noyori O, Saito Y, Takeya H, Baghdadi M, Kitagawa F, Hama N, Ishikawa K, Okuno Y, Nosaka K, Seino KI, Matsuoka M, Suzu S. Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma.
J Clin Exp Hematop. 2018;58(4):152-160. doi: 10.3960/jslrt.18034.
熊本大学との共同研究
Muhammad Baghdadi, 清野研一郎
Interleukin-34, がんの治療標的としての可能性
臨床免疫・アレルギー科；70 (4): 422-428, 2018
Muhammad Baghdadi, Yui Umeyama, Naoki Hama, Takuto Kobayashi, Nanumi Han, Haruka Wada and Ken-ichiro Seino.
Interleukin-34, a comprehensive review.
Journal of Leukocyte Biology 2018:1-21. https://doi.org/10.1002/JLB.MR1117-457R
IL-34発見から10年目の節目を迎え、これまでの報告を網羅的に総括しました。
Muhammad Baghdadi, Kozo Ishikawa, Hiraku Endo, Yui Umeyama, Tsukasa Ataka, Haruka Wada, Yumiko Oyamada, Naoki Hyakushima and Ken-ichiro Seino.
Enhanced expression of IL-34 in an inflammatory cyst of the submandibular gland: a case report.
Inflammation and Regeneration 38:12, 2018. doi.org/10.1186/s41232-018-0069-6
炎症性嚢胞におけるIL-34の発現を示した最初の論文
Nanumi Han, Muhammad Baghdadi, Kozo Ishikawa, Hiraku Endo, Takuto Kobayashi, Haruka Wada, Keisuke Imafuku, Hiroo Hata and Ken-ichiro Seino.
Enhanced IL-34 expression in Nivolumabresistant metastatic melanoma.
Inflammation and Regeneration 38:3, 2018. doi.org/10.1186/s41232-018-0060-2
抗PD-1抗体治療に不応答になったメラノーマ局所におけるIL-34発現を示した世界初の論文
Baghdadi M, Endo H, Takano A, Ishikawa K, Kameda Y, Wada H, Miyagi Y, Yokose T, Ito H, Nakayama H, Daigo Y, Suzuki N, Seino K.
High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers.
Sci Rep. 2018 Jan 11;8(1):418. doi: 10.1038/s41598-017-18796-8.
2016年のCancer Res論文の続報。IL-34とM-CSF発現の関係、CD163陽性TAMの浸潤との関連についての臨床的検討。肺がんの進展や悪性度に関連していることを示した。
2017年
大塚亮、清野研一郎
再生医療時代におけるあらたな移植免疫制御
医学のあゆみ Vol. 263 Nos. 11, 12, 927-931, 2017
大塚亮、和田はるか、ムハンマド・バグダーディー、辻飛雄馬、清野研一郎
多能性幹細胞を用いた免疫寛容誘導
移植 52巻6号 p. 489-494, 2017
ムハンマド・バグダーディー、 遠藤拓、和田はるか、清野研一郎
IL34と腫瘍．臨床免疫・アレルギー科 67: 88-92. 2017.
Baghdadi M, Endo H, Tanaka Y, Wada H, Seino K.
Interleukin 34, from pathogenesis to clinical applications.
Cytokine 99: 139-147, 2017
IL-34に関する珠玉のReview論文
遠藤拓、Muhammad Baghdadi、石川浩三、江澤永倫子、梅山悠伊、和田はるか、鈴木直、清野研一郎
放射線刺激により誘発されるインターロイキン34の放射線治療抵抗性における潜在的役割について
聖マリアンナ医科大学雑誌 vol.45, pp. 173-183, 2017
2016年
和田はるか、ムハンマド・バグダーディー、辻飛雄馬、大塚亮、清野研一郎
iPS細胞からの免疫細胞分化誘導 in iPS細胞の安全・高品質な作製技術, 397-386. 2016. 技術情報教会
Baghdadi M, Wada H, Nakanishi S, Abe H, Han N, Putra WE, Endo D, Watari H, Sakuragi N, Hida Y, Kaga K, Miyagi Y, Yokose T, Takano A, Daigo Y, Seino K.
Chemotherapy-induced IL-34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells.
Cancer Research. pii: canres.1170.2016.
薬剤耐性がんにおけるIL-34の発現と病的機能を世界で初めて発見
ミエロイド系細胞の抑制を誘導する新しい免疫チェックポイント分子を同定したという意義があります
Kanda M, Yamanaka H, Kojo S, Usui Y, Honda H, Sotomaru Y, Harada M, Taniguchi M, Suzuki N, Atsumi T, Wada H, Baghdadi M, Seino K.
Transcriptional regulator Bhlhe40 works as a cofactor of T-bet in the regulation of IFN-γ production in iNKT cell.
Proceedings of the National Academy of Science of the United States of America (PNAS) 113:E3394-402, 2016.
腫瘍免疫や自己免疫疾患に重要なiNKT細胞のIFN-γ産生メカニズムを解明
Miyawaki S, Kawamura Y, Oiwa Y, Shimizu A, Hachiya T, Bono H, Koya I, Okada Y, Kimura T, Tsuchiya Y, Suzuki S, Onishi N, Kuzumaki N, Matsuzaki Y, Narita M, Ikeda E, Okanoya K, Seino K, Saya H, Okano H, and Miura K.
Tumour resistance in induced pluripotent stem cells derived from naked mole-rats.
Nat Commun 2016 May 10;7:11471. doi: 10.1038/ncomms11471.
Hirotake Abe, Haruka Wada, Muhammad Baghdadi, Sayaka Nakanishi, Yuu Usui, Takahiro Tsuchikawa, Toshiaki Shichinohe, Satoshi Hirano and Ken-ichiro Seino.
Identification of a Highly Immunogenic Mouse Breast Cancer Sub Cell Line, 4T1-S.
Human Cell 29: 58-66, 2016. 免疫原性の高いマウス乳がん細胞株４T1-Sを世界で初めて同定
2015年
Wada H, Baghdadi M, Seino K. Generation of T-Lineage Cells from iPS Cells and Its Application.
In Hematopoietic Differentiation of Human Pluripotent Stem Cells, Cheng T, ed. (Heidelberg, Germany: Springer), pp. 81-90, 2015
iPS細胞から作製したT細胞が抗腫瘍効果を発揮する事を示しています
清野研一郎．NKT細胞．
in 免疫力徹底研究、監修：瀬谷司、p. 44-45. 2015. 発行：NPO先端医療を支える会
清野研一郎. 移植における免疫制御の現在・過去・未来．今日の移植 28巻4号、419-423. 2015
臓器移植から細胞移植にわたる免疫制御法に関するレヴュー（邦文）
Wada H, Kudo H, Sasaki H, Baghdadi M, Seino K.
New immune regulation strategy in the age of regenerative medicine using pluripotent stem cells.
Inflammation & Regeneration 35: 238-243, 2015
ES細胞やiPS細胞を用いた再生医療時代における新しい免疫制御法に関するレヴュー
Hayashi E, Hachiya K, Kojo S, Baghdadi M, Takeuchi S, Yamanaka H, Abe H, Wada H and Seino K.
aMSH stimulation contributes to TGF-b1 production via MC1R-MITF signaling pathway in melanoma cell.
Inflammation & Regeneration 35: 244-254, 2015
和田はるか、工藤浩也、佐々木元、ムハンマド・バグダディ、清野研一郎.
多能性幹細胞を用いた再生医療における新しい免疫制御法．日本臨床73巻増刊号; 90-95, 2015
Sasaki H, Wada H, Baghdadi M, Tsuji H, Ohtsuka R, Morita K, Shinohara N and Seino K.
New immunosuppressive cell therapy to prolong survival of iPS cell-derived allografts.
Transplantation 99: 2301-2310, 2015.
邦題：iPS細胞由来アログラフトの生着を延長させる新しい免疫抑制療法
Shintaro Takeuchi, Muhammad Baghdadi, Takahiro Tsuchikawa, Haruka Wada, Toru Nakamura, Hirotake Abe, Sayaka Nakanishi, Yuu Usui, Kohtaro Higuchi, Mizuna Takahashi, Kazuho Inoko, Syoki Sato, Toshiaki Shichinohe, Hironobu Takano, Ken-ichiro Seino and Satoshi Hirano.
Chemotherapy-derived inflammatory responses accelerate the formation of immunosuppressive myeloid cells in the tissue microenvironment of human pancreatic cancer.
Cancer Research 75:2629-40, 2015
邦題：化学療法による炎症反応は膵がん微小環境において免疫抑制細胞の生成を促進する
Muto M, Baghdadi M, Maekawa R, Wada H, and Seino K.
Myeloid molecular characteristics of human γδT cells support their acquisition of tumor antigen-presenting capacity.
Cancer Immunology, Immunotherapy 64:941-9, 2015
邦題：ガンマデルタT細胞のミエロイド細胞的特徴は抗原提示能を獲得するために重要
Nishio K, Miyagi T, Tatsumi T, Mukai K, Yokoyama Y, Yoshioka T, Sakamori R, Hikita H, Kodama T, Shimizu S, Shigekawa M, Nawa T, Yoshihara H, Hiramatsu N, Yamanaka H, Seino K, Takehara T.
Invariant natural killer T cell deficiency leads to the development of spontaneous liver inflammation dependent on γδT cells in mice.
J Gastroenterol 2015 Mar 21
邦題：NKT細胞の欠損はガンマデルタT細胞依存性の炎症を肝臓に引き起こす
Seino K, Wada H, Baghdadi M.
New immunosuppressive strategies for transplantation based on pluripotent stem cell (PSC)-derived immunoregulatory cells.
Stem Cell Transl Invest 2015; 2: e504. doi: 10.14800/scti.504
邦題：多能性幹細胞から誘導された免疫制御細胞による移植のための新しい免疫抑制戦略
2014年
Kudo H, Wada H, Sasaki H, Tsuji H, Otsuka R, Kojo S, Baghdadi M, Chikaraishi T, Seino K.
Induction of macrophage-like immunosuppressive cells from mouse ES cells that contribute to prolong allogeneic graft survival.
PLoS One 9(10): e111826, 2014
邦題：マウスES細胞からのアログラフト生着延長に寄与するマクロファージ様免疫抑制細胞の誘導
清野研一郎、佐藤克明.
臍帯血中免疫細胞の特性. in 臍帯血移植の基礎と臨床、監修：浅野茂隆、谷口克 発行：医学書院
Baghdadi M, Takeuchi S, Wada H, Seino K.
Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response.
mAbs (monoclonal antibodies) 2014 Aug 5;6(5) Epub ahead of print
邦題：抗腫瘍免疫反応の調和を司るTIMタンパク質に対する阻害抗体
Murao N, Seino KI, Hayashi T, Ikeda M, Funayama E, Furukawa H, Yamamoto Y, Oyama A.
Treg-enriched CD4+ T cells attenuate collagen synthesis in keloid fibroblasts.
Exp Dermatol. 2014 Apr;23(4):266-271.
佐々木元、和田はるか、清野研一郎．
再生医療における免疫制御． 最新医学６９巻３月増刊号707-713．
「再生医療最新の進歩、次世代再生医療に向けた基盤研究」
2013年
Wada H, Kojo S, and Seino K.
Mouse models of human INAD by Pla2g6 deficiency.
Histology and histopathology 28(8):965-9, 2013.
工藤浩也、和田はるか、清野研一郎. 移植と免疫. medicina 50巻3号、416-418.
清野研一郎. 移植片に対する反応． in 標準免疫学第３版、監修：谷口克、発行：医学書院
清野研一郎. 移植免疫制御をに担うNKT細胞. 血液フロンティア 23巻7号、41-45．
和田はるか、工藤浩也、清野研一郎. iPS細胞からの免疫細胞分化誘導.
再生医療事業の課題解決のための手引書 情報技術協会刊 2013年
2012年
工藤浩也、和田はるか、清野研一郎.
細胞治療による免疫寛容の誘導. 今日の移植 25巻４号、293-300.
2011年
Hosonuma S, Kobayashi Y, Kojo S, Wada H, Seino K, Kiguchi K, Ishizuka B.
Clinical significance of side population in ovarian cancer cells.
Hum Cell, 24: 9-12, 2011
Kobayashi Y, Seino K, Hosonuma S, Ohara T, Itamochi H, Isonishi S, Kita T, Wada H, Kojo S, Kiguchi K.
Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cicplatin.
Gynecol. Oncol. 121: 390-394, 2011
Wada H, Kojo S, Okamoto N, Satoh Y, Ishizuka B, Seino K.
Successful differentiation to T cells, but unsuccessful B cell generation, from B-cell-derived induced pluripotent stem cells. Int. Immunol. 23: 65-74, 2011
2010年
Ohkubo Y, Iwakawa M, Seino K, Nakawatari M, Wada H, Kamijuku H, Nakamura E,Nakano T, Imai T.
Combining carbon ion radiotherapy and local injection of alpha-galactosylceramide-pulsed dendritic cells inhibits lung metastases in an in vibo murine model.
Int. J. Radiation Oncology Biol. Phys. 78: 1524-1531, 2010
清野研一郎．放射線治療と腫瘍免疫との蜜月. 放射線科学、53:31-36, 2010
神宿元、香城諭、和田はるか、清野研一郎．インフルエンザ感染におけるCTLA4-lgの効果. リウマチ科、43:291-297,2010
和田はるか、清野研一郎． NK細胞・NKT細胞の機能制御分子NotchシグナルによるNK細胞の分子と機能制御.
臨床免疫・アレルギー科、53:126-132,2010
2009年
Azakami K, Sato T, Araya N, Utsunomiya A, Kubota R, Suzuki K, Hasegawa D,Izumi T, Fujita H, Aratani S, Fujii R, Yagishita N, Kamijuku H, Kanekura T,Seino K, Nishioka K, Nakajima T, Yamano Y.
Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders.
Blood, 114:3208-3215, 2009
Wada H, Yasuda T, Miura I, Watabe K, Sawa C, Kamijuku H, Kojo S, Taniguchi M, Nishino I, Wakana S, Yoshida H, and Seino K.
Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6.
Am J Pathol, 175:2257-2263, 2009
Wada H, Kojo S, and Seino K. Suppressor turns into helper. Immunotherapy, 1:737-737 2009
Arase H, and Seino K.
The study of regulatory T cells and NKT cells in Japan: a historical perspective.
Int Immunol, 21:1101-1103, 2009
Wada H, Yanagisawa K, and Seino K.
Cancellation of NKT cell immunosuppression targeting myeloid suppressor cells.
Inflammation and Regeneration 29: 128-130, 2009.
清野研一郎. 担癌状態におけるNKT細胞機能の抑制とその解除. Biotherapy 23: 241-244, 2009.
清野研一郎. 細胞リプログラミング技術を用いた免疫細胞再生医療の開発. 再生医療 8: 322-323, 2009.
2008年
Tashiro T, Hongo N, Nakagawa R, Seino K, Watarai H, Ishii Y, Taniguchi M, and Mori K.
RCAI-17, 22, 24-26, 29, 31, 34-36, 38-40, and 88, the analogs of KRN7000 with a sulfonamide linkage: Their synthesisi and bioactivity for mouse natural killer T cells to produce Th2-biased cytokines.
Bioorg Med Chem 16: 8896-8906, 2008.
Kamijuku H, Nagata Y, Jiang X, Ichinohe T, Tashiro T, Mori K, Taniguchi M, Hase K, Ohno H, Shimaoka T, Yonehara S, Odagiri T, Tashiro M, Sata T, Hasegawa H, and Seino K.
Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide which can induce cross-protection against influenza viruses.
Mucosal Immunology 1: 208-218, 2008.
Hidano S, Sasanuma H, Ohshima K, Seino K, Kumar L, Hayashi K, Hikida M, Kurosaki T, Taniguchi M, Geha RS, Kitamura D, Goitsuka R.
Distinct regulatory functions of SLP-76 and MIST in NK cell cytotoxicity and IFN-gamma production.
Int Immunol 3: 345-352, 2008.
Fuhshuku K, Hongo N, Tashiro T, Masuda Y, Nakagawa R, Seino K, Taniguchi M, Mori K.
RCAI-8, 9, 18, 19, and 49-52, conformationally restricted analogues of KRN7000 with an azetidine or a pyrrolidine ring: Their synthesis and bioactivity for mouse natural killer T cells to produce cytokines.
Bioorg Med Chem 16: 950-964, 2008.
清野研一郎. 細胞リプログラミング技術を用いた免疫細胞再生医療の開発．再生医療 7: 277-278, 2008.
2007年
Shimaoka T, Seino K, Kume N, Minami M, Nishime C, Suematsu M, Kita T, Taniguchi M, Matsushima K, Yonehara S.
Critical Role for CXC Chemokine Ligand 16 (SR-PSOX) in Th1 Response Mediated by NKT Cells.
J Immunol 179: 8172-8179, 2007.
Nagata Y, Kamijuku H, Taniguchi M, Ziegler S, and Seino K.
Differential role of TSLP in the induction of airway hyperreactivity and Th2 immune response in antigen-induced asthma with respect to NKT cell function.
Int Arch Allergy and Imm 144: 305-314, 2007.
Hijikata A, Kitamura H, Kimura Y, Yokoyama R, Aiba Y, Bao Y, Fujita S, Hase K, Hori S, Ishii Y, Kanagawa O, Kawamoto H, Kawano K, Koseki H, Kubo M, Kurita M, Kurosaki T, Masuda K, Nakata M, Oboki K, Ohno H, Okamoto M, Okayama Y, O-Wang J, Saito H, Saito T, Sakuma M, Sato K, Seino K, Setoguchi R, Tamura Y, Tanaka M, Taniguchi M, Taniuchi I, Teng A, Watanabe T, Yamasaki S, Ohara O.
Construction of an open-access database that integrates cross-reference information from the transcriptome and proteome of immune cells.
Bioinformatics 23: 2934-2941, 2007.
Jiang X, Kojo S, Harada M, Ohkohchi N, Taniguchi M, and Seino K.
Mechanism of NKT cell-mediated transplant tolerance.
Am J Transplant 7: 1482-1490, 2007.
清野研一郎. 関節リウマチにおける調節性Ｔ細胞の役割．リウマチ科 38: 561-564, 2007.
清野研一郎. 免疫異常 in リウマチ・アレルギー学 日本医事新報 4323: 69-70, 2007.
清野研一郎. 移植と免疫応答. 臨床検査 51: 105-111, 2007.
和田はるか. NK細胞分化の制御シグナル一サイトカイン、Notchシグナル、受容体型チロシンキナーゼ. 実験医学 25: 1308-1314, 2007.
2006年
Harada M, Magara-Koyanagi K, Watarai H, Nagata Y, Ishii Y, Kojo S, Horiguchi S, Okamoto Y, Nakayama T, Suzuki N, Yeh WC, Akira S, Kitamura H, Ohara O, Seino K, and Taniguchi M. IL-21-induced Be cell apoptosis mediated by natural killer T cells suppresses IgE responses. J Exp Med 203: 2929-2937, 2006.
Yanagisawa K, Exley MA, Jiang X, Ohkochi N, Taniguchi M, and Seino K. Hyporesponsiveness to NKT cell ligand a-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide. Cancer Research 66: 11441-11446, 2006.
Seino K, Motohashi S, Fujisawa T, Nakayama T, and Taniguchi M. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci. 97: 807-812, 2006.
Ueda N, Kuki H, Kamimura D, Sawa S, Seino K, Tashiro T, Fushuku K, Taniguchi M, Hirano T, and Murakami M. CD1d-restricted NKT cell activation enhanced homeostatic proliferation of CD8+ T cells in a manner dependent on IL-4. Int. Immunol. 18: 1397-1340, 2006.
Jiang X, Morita M, Sugioka A, Harada M, Kojo S, Wakao H, Watarai H, Ohkohchi N, Taniguchi M, and Seino K. The importance of CD25+CD4+ regulatory T cells in mouse hepatic allograft tolerance. Liver Transplantation 12: 1112-1118, 2006.
Fujita S, Seino K, Sato K, Sato Y, Eizumi K, Yamashita N, Taniguchi M, and Sato K. Regulatory dendritic cells act as regulators of acute lethal systemic inflammatory response. Blood 107: 3656-3664, 2006.
清野研一郎. 免疫系におけるNKT細胞の役割. 臨床免疫 451: 578-583, 2006.
2005年以前
Seino K and Taniguchi M. Functionally different NKT cell subsets. J. Exp. Med. 202: 1623-1626, 2005.
Kojo S, Seino K, Harada M, Watarai H, Wakao H, Uchida T, Nakayama T, and Taniguchi M. Induction of regulatory properties in dendritic cells by Va14 NKT cells. J. Immunol. 175: 3648-55, 2005.
Bashuda H, Kimikawa M, Seino K, Kato Y, Ono F, Shimizu A, Yagita H, Teraoka S, and Okumura K, Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J. Clin. Invest. 115: 1896-1902, 2005.
Seino K, Fujii S, Harada M, Motohashi S, Nakayama T, Fujisawa T, Taniguchi M. Va14 NKT cell-mediated anti-tumor responses and their clinical application. Springer Seminars in Immunopathology 27:9253-9257, 2005.
Jiang X, Shimaoka T, Kojo S, Harada M, Watarai H, Wakao H, Ohkohchi N, Yonehara S, Taniguchi M, and Seino K. Critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance. J. Immunol. 175: 2051-2055, 2005.
Inoue K, Wakao H, Ogonuki N, Miki H, Seino K, Numbu W, Noda S, Miyoshi H, Koseki H. Taniguchi M, and Ogura A. Generation of Cloned Mice by Direct Nuclear Transfer from Natural Killer T Cells. Current Biology 15: 1114-1118, 2005.
Yamauchi T, Ishibashi A, Shikata K, Tokuhara N, Seino K, Kobayashi S, and Nagai M. Effect of E6060[4-{5-[7-Fluoro-4-(trifluoromethyl)benzo[b]furan-2-yl]-1H-2-pyrroly}benzoic Acid], a Novel Subtype-Selective Retinoid, on Lupus-Like Nephritis in Female(NZB_NZW)F1 Mice. J. Pharmacol. Exp. Ther. 312: 938-944, 2005.
Seino K, and Taniguchi M. NKT Cells: A Regulator in Both Innate and Acquired Immunity. Current Medical Chemistry 4: 59-64, 2005.
清野研一郎. レチノイン酸レセプターα－選択的アゴニストによる急性および慢性移植拒絶反応の抑制. 臨床免疫 43: 79-81, 2005.
Seino K, and Taniguchi M. Functional Roles of NKT cells in the immune system. Frontiers in Bioscience 9: 2577-2587, 2004.
Seino K, Yamauchi T, Shikata K, Kobayashi S, Nagai M, Taniguchi M, and Fukao K. Prevention of acute and chronic allograft rejection by a novel retinoic acid receptor-alpha-selective agonist. Int. Immunol. 16: 665-673, 2004.
Shimizu E, Koike J, Wakao H, Seino K, Koseki H, Kakiuchi T, Nakayama T, and Taniguchi M. Role of a NK receptor, KLRE-1, in bone marrow allograft rejection: analysis with KLRE-1 deficient mice. Blood 104: 781-783, 2004.
Seino K, Harada M, and Taniguchi M. NKT cells are relatively anti-apoptotic. Trends in Immunology 25: 219-221, 2004.
Harada M, Seino K, Wakao H, Sakata S, Ishizuka Y, Ito T, Kojo S, Nakayama T, and Taniguchi M. Down-regulation of invariant Va14 antigen receptor in NKT cells upon activation. Int. Immunol. 16: 241-247, 2004.
Kobayashi S, Kaneko Y, Seino K, Yamada Y, Motohashi S, Koike J, Sugaya K, Kuriyama T, Asano S, Tsuda T, Wakao H, Harada M, Kojo S, Nakayama T, and Taniguchi M. Impaired IFN-g production of Va24 NKT cells in non-remitting sarcoidosis. Int. Immunol. 16: 215-222, 2004.
Koike J, Wakao H, Ishizuka Y, Sato T, Hamaoki M, Seino K, Koseki H, Nakayama T, and Taniguchi M. Bone marrow allograft rejection mediated by a novel murine NK receptor, NKG2I. J. Exp. Med., 199: 137-144, 2004.
清野研一郎. NKT細胞による免疫制御のメカニズム. 炎症と免疫 12: 28-32, 2004.
Taniguchi M, Seino K, and Nakayama T. The NKT cell system: bridging innate and acquired immunity. Nature Immunol. 4: 1164-1165, 2003.
清野研一郎、谷口克. iNKT細胞による自然免疫および獲得免疫の制御. Annual Review 免疫 2004, 127-134, 2003.
Yanagisawa K, Seino K, Nozue M, Todoroki T, and Fukao K. Impaired proliferative response of Valpha24 NKT cells from cancer patients against alpha-galactosylceramide. J. Immunol. 168: 6494-6499, 2002.
Seino K, Setoguchi Y, Ogino T, Kayagaki N, Akiba H, Nakano H, Taniguchi H, Takada Y, Todoroki T, Fukuchi Y, Yagita H, Okumura K, and Fukao K. Protection against Fas-and TNF receptor 1-mediated liver injury by blockade of FADD without loss of NF-kappa B activation. Annals of Surgery 234: 681-688, 2001.
Seino K, Fukao K, Muramoto K, Yanagisawa K, Takada Y, Kakuta S, Iwakura Y, Luc Van Kaer, Takeda K, Nakayama T, Taniguchi M, Bashuda H, Yagita H, and Okumura K. Requirement of natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci USA 98: 2577-2581, 2001.
Takada Y, Hori T, Yuzawa K, Seino K, Taniguchi H, Otsuka M, and Kaneko M, . Living donor with type IV-A choledochal cyst in liver transplantation. Transplantation 72: 551-552, 2001.
清野研一郎. 移植免疫におけるNKT細胞の役割-臨床応用の可能性. 医学のあゆみ 199: 487-489, 2001.
清野研一郎. 免疫制御機構におけるNKT細胞の役割. 炎症と免疫 9: 531-535, 2001.
清野研一郎. 副刺激の阻害による寛容誘導. 医学のあゆみ 196: 949-952, 2001.
Seino K, Nishimori I, NagaiY, Inoue H, Takada Y, Adachi S, Todoroki T, and Fukao K. Idiopathic calcifying pancreatitis; case report of a Japanese pediatric patient. J. Gastroenterology. 35: 941-944, 2000.
Gu M, Takada Y, Fukunaga K, Ishiguro S, Taniguchi H, Seino K, Yuzawa K, Otsuka M, Todoroki T, and Fukao K. Pharmacologic graft protection without donor pretreatment in liver transplantation from non-heart-beating donors. Transplantation 70: 1021-1025, 2000.
Taniguchi H, Kondo R, Suzuki A, Zheng YW, Takada Y, Fukunaga K, Seino K, Yuzawa K, Otsuka M, Fukao K, and Nakauchi H. Clonogenic colony-forming ability of flow cytometrically isolated hepatic progenitor cells in the murine fetal liver. Cell Transplant. 9: 697-700, 2000.
Seino K, Kayagaki N, Yamaguchi N, Takada Y, Uyama S, Kiuchi T, Tanaka K, Yagita H, Okumura K, and Fukao K. Soluble forms of CD95 and CD95 ligand after living related liver transplantation. Transplantation 67: 634-636, 1999.
Fukunaga K, Takada Y, Taniguchi H, Mei G, Seino K, Yuzawa K, Otsuka M, Todoroki T, Goto K, and Fukao K. Endothelin antagonist treatment for successful liver transplantation from non-heart-beating donors. Transplantation 67: 328-332, 1999.
Seino K, Iwabuchi K, Kayagaki N, Miyata R, Nagaoka I, Matsuzawa A, Fukao K, Yagita H. and Okumura K. Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol.161: 4484-4488, 1998.
Allison J, Seino K, and Yagita H. Can expression of CD95 (Fas/APO-1) ligand on grafts or tumor cells prevent their rejection? Springer Seminars in Immunopathology 19: 311-322, 1998.
Horimoto H, Nozawa M, Kokudo N, Nakao M, Takahashi S, Miyasaka M, Seino K, Yagita H, and Okumura K. Immunoregulation via adhesion molecules in allogenic and xenogenic hepatocyte transplantation to Nagata's analbuminemic rats. Cell Transplantation 6: 535-536, 1997.
Seino K, Kayagaki N, Tsukada N, Fukao K, Yagita H, and Okumura K. Transplantation of CD95 ligand-expressing grafts: Influence of transplantation site and difficulty to protect allo- and xeno-grafts. Transplantation 64: 1050-1054, 1997.
Seino K, Kayagaki N, Takeda K, Fukao K, Okumura K, and Yagita H. Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology 113: 1315-1322, 1997.
Seino K, Kayagaki N, Okumura K, and Yagita H. Antitumor effect of locally produced CD95 ligand. Nature Medicine 3: 165-170, 1997.
Bashuda H, Seino K, Ra C, Yagita H, and Okumura K. Lack of cognate help by CD4+ T cells and anergy of CD8+ T cells are the principal mechanisms for anti-leukocyte function-associated antigen-1/intercellular adhesion molecule-1-induced cardiac allograft tolerance. Transplantation 63: 113-118, 1997.
Seino K, Kayagaki N, Bashuda H, Okumura K, and Yagita H. Contribution of Fas ligand to cardiac allograft rejection. Int. Immunol. 8, 1347-1354, 1996.
Yagita H, Seino K, Kayagaki N, and Okumura K. CD95 li16gand in graft rejection. Nature 379: 682, 1996.
Seino K, Azuma M, Bashuda H, Fukao K, Yagita H, and Okumura K. CD86 (B70/B7-2) on endothelial cells costimulates allogeneic CD4+ T cells. Int. Immunol.7: 1331-1337, 1995.